Intravenous Administration of Human γ-Globulin

Barandun, S.; Kistler, P.; Jeunet, F.; Isliker, H.

doi:10.1159/000464763

Cited by 93 publications

(124 citation statements)

References 3 publications

(3 reference statements)

Supporting

Mentioning

118

Contrasting

Unclassified

Order By: Relevance

“…Early IVIG preparations were produced from ISG by digestion with proteolytic enzymes to eliminate anticomplement activity. Anticomplement activity was believed to be the primary cause of adverse side-reactions when ISG was injected intravenously (Barandun et al 1962). The first commercial IVIG was produced by digestion of ISG with pepsin.…”

Section: Intravenous Immunoglobulin (Ivig)mentioning

confidence: 99%

“…Other early IVIG manufacturing procedures involved treatment of ISG with enzymes or with chemical reagents that reacted with amino acids located in the complement binding site (Barandun et al 1962;Sgouris 1967;Schroeder et al 1980). Unfortunately, each of these modifications reduced important antibody activities (Pollack 1983;Kim et al 1986;Bender and Hetherington 1987;Steele and Steele 1989) and shortened the half-lives of some antibodies (Janeway et al 1968;Winston et al 1982;Hagenbeek et al 1987Hagenbeek et al -1928.…”

Section: Intravenous Immunoglobulin (Ivig)mentioning

confidence: 99%

See 1 more Smart Citation

The history and evolution of immunoglobulin products and their clinical indications

Hooper¹

2015

LymphoSign Journal

View full text Add to dashboard Cite

The history of providing antibodies to treat diseases began in the 19th century with the discovery of tetanus and diphtheria toxins and the demonstration that immunity to tetanus and diphtheria infections could be transferred by immune sera. Characterization of the mediators of this immunity resulted in the discovery that antibodies are proteins that can be isolated and used to protect against infectious diseases. Development of a method to isolate antibodies from human plasma that could be safely injected into people initiated the development of human gamma globulin preparations to provide antibodies to patients with inherited antibody deficiencies. To overcome the limitations imposed by intramuscular injection of gamma globulin, intravenous gamma globulin preparations were developed that began to be used in a wide variety of clinical conditions. Thus the original clinical indication for infection prevention was expanded to several other indications that employ large doses to suppress inflammatory and autoimmune disorders. The most recent development in immunoglobulin therapy is the production of concentrated immune globulins for subcutaneous injection. Home infusions of subcutaneous immunoglobulin are increasingly used to treat immunodeficient patients and are being studied for other clinical applications.

show abstract

Section: Intravenous Immunoglobulin (Ivig)mentioning

confidence: 99%

Section: Intravenous Immunoglobulin (Ivig)mentioning

confidence: 99%

The history and evolution of immunoglobulin products and their clinical indications

Hooper¹

2015

LymphoSign Journal

View full text Add to dashboard Cite

show abstract

“…These heterogeneities include aggregation, fragmentation, deamidation, oxidation, N-and C-terminal differentiations. [2][3][4][5][6][7][8][9][10][11] Several analytical methods have been developed for these purposes, for example, SDS polyacrylamide gel electrophoresis for the determination of the purity of proteins, size exclusion chromatography for aggregation, ion exchange chromatography or hydrophobic interaction chromatography for the detection of deamidation and oxidation variants, and Ellman's assay for quantification of free thiol groups. 12,13 Capillary-based SDS electrophoresis (CE-SDS) is one version of the capillary gel electrophoresis (CGE) using soluble linear polymers.…”

Section: Introductionmentioning

confidence: 99%

Application of Microchip Electrophoresis Sodium Dodecyl Sulfate for the Evaluation of Change of Degradation Species of Therapeutic Antibodies in Stability Testing

et al. 2014

View full text Add to dashboard Cite

We evaluated the performance of a commercial microchip electrophoresis instrument (LabChip ® GXII) for the evaluation of change of degradation species of therapeutic antibodies in stability testing. This system requires a sample volume of only 5 μg, and indicates fine resolution of size variant species such as light chain, heavy chain, non-glycosylated heavy chain and various degradation species. Precision and accuracy were high; the intermediate precision of 18 determinations was only 2.1% or less as RSD and recoveries ranged from 97.8 to 103.0% for major species as heavy chain, light chain and intact molecule of a therapeutic antibody. The applicability of this method was demonstrated by applying the method for the analysis of heat-degraded products of three pharmaceutical antibodies. Though some fragment peaks commonly appeared and increased according to temperature regardless of the source of preparations, one of them indicated specific peaks implying the cleavage of the peptide chain of the heavy chain. We also compared the performance of the method with those using conventional capillary-based SDS electrophoresis. Although the absolute purity values expressed as peak area % were different for the two methods, probably due to the difference in the detection methods, similar quality profiles were obtained within 40 s by microchip-based SDS electrophoresis. In addition, the degradation manner of three marketed antibodies depending on temperature was almost the same for the two methods. At the first stage in the development of manufacturing antibody pharmaceuticals, various factors including cell selection, cell cultivation, and formulation development should be evaluated using limited sample amounts. The stability testing using microchip-based electrophoresis seems suitable for these purposes.

show abstract

“…Importantly, it was recognized that harsh chemical or enzymatic treatment of IgG may damage the molecule and reduce or abolish its natural function (1,18). A number of methods have now been developed for preparing gamma globulin for intravenous infusion, including chemical or enzyme treatment, acidification, and column chromatography.…”

Section: Introductionmentioning

confidence: 99%

Newer uses of intravenous immunoglobulins as anti-infective agents

Pennington

1990

Antimicrob Agents Chemother

View full text Add to dashboard Cite

Intravenous Administration of Human γ-Globulin

Cited by 93 publications

References 3 publications

The history and evolution of immunoglobulin products and their clinical indications

The history and evolution of immunoglobulin products and their clinical indications

Application of Microchip Electrophoresis Sodium Dodecyl Sulfate for the Evaluation of Change of Degradation Species of Therapeutic Antibodies in Stability Testing

Newer uses of intravenous immunoglobulins as anti-infective agents

Contact Info

Product

Resources

About